medicalxpress - A patient of mine, a veteran who had tried to quit smoking for over a decade, told me that after he started a GLP-1 drug for his diabetes, he lost interest in cigarettes. He didn't use a patch. He didn't set a quit date. He simply lost interest. It happen…
#obesity #healthcare #pharmaceuticals #elililly #novonordisk #weightloss #publichealth #drugdevelopment #behavioralhealth
Friday, March 6, 2026, 12:23 pm / permalink 20276 / 8 stories in 4 days
Eli Lilly launches Employer Connect to broaden GLP‑1 coverage (3 days)
Novo Nordisk commits $2.1B to Vivtex to pursue oral obesity medicines (8 days)
Lilly’s Zepbound bests Novo’s CagriSema in head‑to‑head obesity trial (13 days)
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.